Page 2 - Dr Reddy's Lab
Duvvada unit audit: Dr Reddy's to launch corrective plan post verdict
Hyderabad, 8 September: Sending the remediation steps of Dr Reddy's Laboratories Limited for a toss, German Regulatory Authory has issued six major audit observations on the company's Duvvada formulations manufacturing plant, months after the US Food and Drug Administration(US FDA) slapped the facility with Form 483 with the highest number of 13 observations in a re-inspection sought by the company.This is the second instance where Dr Reddy's manufacturing facility has fallen short of quality compliances during a month's time. The German regulatory body had told the company last month that it was not going to renew the compliance certification of Unit 2 at Bachupally in Hyderabad, thus effectively halting the product exports to the EU member countries from that plant.There are no immediate financial implications from the latest regulatory action as Duvvada facility already stopped exporting any product to Europe.The development, however, raised serious doubts over the effectiveness ..
 "Duvvada unit audit: Dr Reddy's to launch corrective plan post verdict")
Dr Reddy's launches schizophrenia drug in the US market
Aripiprazole is a therapeutic equivalent generic version of Ablify tablets in the US market
 "Dr Reddy's launches schizophrenia drug in the US market")
Dr Reddy's enters Dow Jones Indices
Company recognised for its corporate sustainability leadership, is sole pharma firm in index of emerging markets
Dr Reddy's to buy eight ANDAs in US for $350 million
ANDAs comprise of complex generic products across diverse dosage forms
 "Dr Reddy's to buy eight ANDAs in US for $350 million")
Dr Reddy's buyback to cushion downside
Most important positive for the stock will be the resolution of the US inspector issues